Elanco Animal Health (ELAN)

• Market cap: $4.21B
• 1 day: 0.47%
• 5 days: -3.85%
• 1 month: -19.47%
• 3 months: -29.57%
• 6 months: -32.81%
• Year to date: -29.63%
• 1 year: -34.42%
• 5 years: -64.49%
• 10 years: -76.44%
• Sector: Healthcare
• Industry: Drug Manufacturers - Specialty & Generic

About: Elanco Animal Health is an animal health company that is engaged in developing, manufacturing, and marketing pharma products for companion and food animals. It spun off from Eli Lilly in 2018 and acquired Janssen Animal Health in 2011, Novartis Animal Health in 2014, Boehringer Ingelheim Vetmedica in 2017, and Bayer Animal Health in 2020. The company's operations are conducted globally, and it sells its products in over 90 countries. It offers a range of food animal products used in cattle, sheep, goats, and swine production.

Employees: 9,450

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

31% more call options, than puts

Call options by funds: $23.3M | Put options by funds: $17.8M

17% more first-time investments, than exits

New positions opened: 63 | Existing positions closed: 54

2.23% more ownership

Funds ownership: 96.75% [Q3] → 98.98% (+2.23%) [Q4]

1% more funds holding

Funds holding: 383 [Q3] → 385 (+2) [Q4]

0% more repeat investments, than reductions

Existing positions increased: 137 | Existing positions reduced: 137

16% less capital invested

Capital invested by funds: $7.02B [Q3] → $5.93B (-$1.09B) [Q4]

57% less funds holding in top 10

Funds holding in top 10: 7 [Q3] → 3 (-4) [Q4]

Research analyst outlook

5 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $12 42% upside
• Avg. target: $14.80 75% upside
• High target: $19 124% upside

5 analyst ratings

• positive: 3 60%
• neutral: 2 40%
• negative: 0 0%

Stifel Jonathan Block 0% 1-year accuracy 0 / 20 met price target	53% upside $13	Buy Maintained	14 Apr 2025
Piper Sandler David Westenberg 43% 1-year accuracy 18 / 42 met price target	42% upside $12	Neutral Maintained	6 Mar 2025
UBS Andrea Alfonso 0% 1-year accuracy 0 / 2 met price target	100% upside $17	Buy Maintained	26 Feb 2025
Morgan Stanley Erin Wright 52% 1-year accuracy 13 / 25 met price target	53% upside $13	Equal-Weight Maintained	26 Feb 2025
Barclays Balaji Prasad 16% 1-year accuracy 7 / 44 met price target	124% upside $19	Overweight Maintained	26 Feb 2025